148 related articles for article (PubMed ID: 33465826)
1. DNA damage-inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression.
Vargas AC; Chan NL; Wong DD; Zaborowski M; Fuchs TL; Ahadi M; Clarkson A; Sioson L; Sheen A; Maclean F; Bonar F; Cheah A; Jones M; Chou A; Gill AJ
Histopathology; 2021 Jul; 79(1):106-116. PubMed ID: 33465826
[TBL] [Abstract][Full Text] [Related]
2. Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.
Baranov E; Black MA; Fletcher CDM; Charville GW; Hornick JL
Mod Pathol; 2021 Jul; 34(7):1367-1372. PubMed ID: 33731886
[TBL] [Abstract][Full Text] [Related]
3. Expression of CTAG1B clone EPR13780 versus
Abdelaziz MM; Tayel HY; Abdel-Bary A; Badawy OM
J Histotechnol; 2022 Jun; 45(2):56-65. PubMed ID: 34845972
[TBL] [Abstract][Full Text] [Related]
4. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
[TBL] [Abstract][Full Text] [Related]
5. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
[TBL] [Abstract][Full Text] [Related]
6. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
7. Myxoid liposarcoma with cartilaginous differentiation showing
Suzuki K; Yasuda T; Watanabe K; Hori T; Kanamori M; Kimura T
Oncol Lett; 2017 Dec; 14(6):6789-6794. PubMed ID: 29181103
[TBL] [Abstract][Full Text] [Related]
8. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
[TBL] [Abstract][Full Text] [Related]
9. Well-Differentiated Liposarcoma of the Hypopharynx Exhibiting Myxoid Liposarcoma-like Morphology with MDM2 and DDIT3 Co-Amplification.
Murshed KA; Abo Samra H; Ammar A
Head Neck Pathol; 2022 Mar; 16(1):288-293. PubMed ID: 34089125
[TBL] [Abstract][Full Text] [Related]
10. Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma.
Mantilla JG; Ricciotti RW; Chen EY; Liu YJ; Hoch BL
Mod Pathol; 2019 Apr; 32(4):585-592. PubMed ID: 30420727
[TBL] [Abstract][Full Text] [Related]
11. Gene of the month: DDIT3.
Diaz-Perez JA; Kerr DA
J Clin Pathol; 2024 Mar; 77(4):211-216. PubMed ID: 38053287
[TBL] [Abstract][Full Text] [Related]
12. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
Hei SM; Wei HJ; Chen H; Wang JG
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
[No Abstract] [Full Text] [Related]
13. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
Hemminger JA; Iwenofu OH
Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
[TBL] [Abstract][Full Text] [Related]
14. Primary subcutaneous myxoid liposarcoma: a clinicopathologic review of three cases with molecular confirmation and discussion of the differential diagnosis.
Buehler D; Marburger TB; Billings SD
J Cutan Pathol; 2014 Dec; 41(12):907-15. PubMed ID: 25376660
[TBL] [Abstract][Full Text] [Related]
15. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
[TBL] [Abstract][Full Text] [Related]
16. Myxoid Liposarcoma: How to Stage and Follow.
Ho TP
Curr Treat Options Oncol; 2023 Apr; 24(4):292-299. PubMed ID: 36867390
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
18. [Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas].
Xiang H; Wang J; Sun MH; Lu L; Shui RH; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):28-32. PubMed ID: 15796878
[TBL] [Abstract][Full Text] [Related]
19. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.
Kojima N; Kubo T; Mori T; Satomi K; Matsushita Y; Iwata S; Yatabe Y; Ichimura K; Kawai A; Ichikawa H; Yoshida A
Virchows Arch; 2024 Jan; 484(1):71-81. PubMed ID: 37704823
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of two novel patient-derived myxoid liposarcoma cell lines.
Noguchi R; Yoshimatsu Y; Sin Y; Tsuchiya R; Ono T; Akiyama T; Hirabayashi K; Ozawa I; Nakagawa R; Kikuta K; Kondo T
Hum Cell; 2022 Jul; 35(4):1279-1289. PubMed ID: 35637403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
